Gabriella Pellegriti

List of Publications by Year
in descending order

63	5,825	159358 30	118652 62
papers	citations	h-index	g-index

69	69	69	5286
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	European consensus for the management of patients with differentiated thyroid carcinoma of the follicular epithelium. European Journal of Endocrinology, 2006, 154, 787-803.	1.9	1,804
2	Worldwide Increasing Incidence of Thyroid Cancer: Update on Epidemiology and Risk Factors. Journal of Cancer Epidemiology, 2013, 2013, 1-10.	0.5	936
3	Clinical Behavior and Outcome of Papillary Thyroid Cancers Smaller than 1.5 cm in Diameter: Study of 299 Cases. Journal of Clinical Endocrinology and Metabolism, 2004, 89, 3713-3720.	1.8	299
4	Levothyroxine Monotherapy Cannot Guarantee Euthyroidism in All Athyreotic Patients. PLoS ONE, 2011, 6, e22552.	1.1	234
5	Impact of monitoring plasma 1,1-dichlorodiphenildichloroethane (o,p?DDD) levels on the treatment of patients with adrenocortical carcinoma. Cancer, 2001, 92, 1385-1392.	2.0	222
6	BRAF(V600E) mutation and the biology of papillary thyroid cancer. Endocrine-Related Cancer, 2008, 15, 191-205.	1.6	210
7	Italian consensus on diagnosis and treatment of differentiated thyroid cancer: joint statements of six Italian societies. Journal of Endocrinological Investigation, 2018, 41, 849-876.	1.8	165
8	Papillary Thyroid Cancer Incidence in the Volcanic Area of Sicily. Journal of the National Cancer Institute, 2009, 101, 1575-1583.	3.0	138
9	Long-term outcome of medullary thyroid carcinoma in patients with normal postoperative medical imaging. British Journal of Cancer, 2003, 88, 1537-1542.	2.9	129
10	Treatment of advanced medullary thyroid cancer with an alternating combination of doxorubicin-streptozocin and 5 FU-dacarbazine. British Journal of Cancer, 2000, 83, 715-718.	2.9	119
11	Outcome of Differentiated Thyroid Cancer in Gravesâ€™ Patients1. Journal of Clinical Endocrinology and Metabolism, 1998, 83, 2805-2809.	1.8	115
12	Risk-Adapted Management of Differentiated Thyroid Cancer Assessed by a Sensitive Measurement of Basal Serum Thyroglobulin. Journal of Clinical Endocrinology and Metabolism, 2011, 96, 1703-1709.	1.8	108
13	Outcome of Differentiated Thyroid Cancer in Graves' Patients. Journal of Clinical Endocrinology and Metabolism, 1998, 83, 2805-2809.	1.8	98
14	Papillary Thyroid Microcarcinomas: A Comparative Study of the Characteristics and Risk Factors at Presentation in Two Cancer Registries. Journal of Clinical Endocrinology and Metabolism, 2013, 98, 1427-1434.	1.8	80
15	Long-term outcome of patients with insular carcinoma of the thyroid. Cancer, 2002, 95, 2076-2085.	2.0	77
16	Differentiated thyroid cancer in children and adolescents. Journal of Endocrinological Investigation, 2002, 25, 18-24.	1.8	73
17	Real-world efficacy and safety of lenvatinib: data from a compassionate use in the treatment of radioactive iodine-refractory differentiated thyroid cancer patients in Italy. European Journal of Cancer, 2019, 118, 35-40.	1.3	70
18	Increased Mortality in Patients With Differentiated Thyroid Cancer Associated With Graves' Disease. Journal of Clinical Endocrinology and Metabolism, 2013, 98, 1014-1021.	1.8	66

#	Article	IF	Citations
19	Time to Separate Persistent From Recurrent Differentiated Thyroid Cancer: Different Conditions With Different Outcomes. Journal of Clinical Endocrinology and Metabolism, 2019, 104, 258-265.	1.8	48
20	Usefulness of Recombinant Human Thyrotropin in the Radiometabolic Treatment of Selected Patients with Thyroid Cancer. Thyroid, 2001, 11, 1025-1030.	2.4	46
21	Thyroid Cancer in Thyroglossal Duct Cysts Requires a Specific Approach due to Its Unpredictable Extension. Journal of Clinical Endocrinology and Metabolism, 2013, 98, 458-465.	1.8	46
22	The influence of the environment on the development of thyroid tumors: a new appraisal. Endocrine-Related Cancer, 2014, 21, T235-T254.	1.6	46
23	Outcome of the Diffuse Sclerosing Variant of Papillary Thyroid Cancer: A Meta-Analysis. Thyroid, 2016, 26, 1285-1292.	2.4	40
24	Gastroenteropancreatic neuroendocrine tumor metastases to the thyroid gland: differential diagnosis with medullary thyroid carcinoma. European Journal of Endocrinology, 1999, 140, 187-191.	1.9	39
25	Descriptive Epidemiology of Human Thyroid Cancer: Experience From a Regional Registry and The â€œVolcanic Factorâ€. Frontiers in Endocrinology, 2013, 4, 65.	1.5	39
26	Latero-cervical lymph node metastases (N1b) represent an additional risk factor for papillary thyroid cancer outcome. Journal of Endocrinological Investigation, 2017, 40, 1355-1363.	1.8	37
27	Familial Non-Medullary Thyroid Cancer Represents an Independent Risk Factor for Increased Cancer Aggressiveness: A Retrospective Analysis of 74 Families. Frontiers in Endocrinology, 2015, 6, 117.	1.5	35
28	Update on thyroid cancer treatment. Future Oncology, 2012, 8, 1331-1348.	1.1	33
29	Prognostic Factors for Adrenocortical Carcinoma Outcomes. Frontiers in Endocrinology, 2016, 7, 99.	1.5	33
30	The diagnostic use of the rhTSH/thyroglobulin test in differentiated thyroid cancer patients with persistent disease and low thyroglobulin levels. Clinical Endocrinology, 2003, 58, 556-561.	1.2	30
31	TheBRAF^{V600E}Mutation Influences the Short- and Medium-Term Outcomes of Classic Papillary Thyroid Cancer, But Is Not an Independent Predictor of Unfavorable Outcome. Thyroid, 2014, 24, 1267-1274.	2.4	30
32	Recommendations for post-surgical thyroid ablation in differentiated thyroid cancer: a 2015 position statement of the Italian Society of Endocrinology. Journal of Endocrinological Investigation, 2016, 39, 341-347.	1.8	30
33	Safety and Quality-of-Life Data from an Italian Expanded Access Program of Lenvatinib for Treatment of Thyroid Cancer. Thyroid, 2021, 31, 224-232.	2.4	30
34	Mitotane treatment in patients with adrenocortical cancer causes central hypothyroidism. Clinical Endocrinology, 2016, 84, 614-619.	1.2	26
35	Association of autoimmune thyroid diseases, chronic atrophic gastritis and gastric carcinoid: experience from a single institution. Journal of Endocrinological Investigation, 2016, 39, 779-784.	1.8	25
36	Heavy Metals in the Environment and Thyroid Cancer. Cancers, 2021, 13, 4052.	1.7	24

#	Article	IF	Citations
37	Immunostaining for Met/HGF Receptor May be Useful to Identify Malignancies in Thyroid Lesions Classified Suspicious at Fine-Needle Aspiration Biopsy. Thyroid, 2001, 11, 783-787.	2.4	23
38	The tall cell variant of papillary thyroid carcinoma: clinical and pathological features and outcomes. Journal of Endocrinological Investigation, 2013, 36, 249-54.	1.8	22
39	Increased Thyroid Cancer Incidence in Volcanic Areas: A Role of Increased Heavy Metals in the Environment?. International Journal of Molecular Sciences, 2020, 21, 3425.	1.8	20
40	Tall cell and diffuse sclerosing variants of papillary thyroid cancer: outcome and predicting value of risk stratification methods. Journal of Endocrinological Investigation, 2017, 40, 1235-1241.	1.8	19
41	Lymph node location is a risk factor for papillary thyroid cancer-related death. Journal of Endocrinological Investigation, 2018, 41, 1349-1353.	1.8	19
42	Cardiac Arrest After Intravenous Calcium Administration for Calcitonin Stimulation Test. Thyroid, 2014, 24, 606-607.	2.4	17
43	Thyroid Cancer in the Pediatric Age in Sicily: Influence of the Volcanic Environment. Anticancer Research, 2017, 37, 1515-1522.	0.5	17
44	False positive 131I total body scan due to bilateral polycystic renal disease. Journal of Endocrinological Investigation, 1997, 20, 342-344.	1.8	15
45	Several Site-specific Cancers are Increased in the Volcanic Area in Sicily. Anticancer Research, 2015, 35, 3995-4001.	0.5	13
46	Concentration of Metals and Trace Elements in the Normal Human and Rat Thyroid: Comparison with Muscle and Adipose Tissue and Volcanic Versus Control Areas. Thyroid, 2020, 30, 290-299.	2.4	11
47	Differentiated thyroid cancer in children: Heterogeneity of predictive risk factors. Pediatric Blood and Cancer, 2018, 65, e27226.	0.8	10
48	Effect of low-dose tungsten on human thyroid stem/precursor cells and their progeny. Endocrine-Related Cancer, 2019, 26, 713-725.	1.6	10
49	Anaplastic Thyroid Cancer in Sicily: The Role of Environmental Characteristics. Frontiers in Endocrinology, 2017, 8, 277.	1.5	9
50	Editorial: Clinical and Molecular Epidemiology of Thyroid Cancer of Follicular Origin. Frontiers in Endocrinology, 2018, 9, 67.	1.5	7
51	Thyroidectomy as Treatment of Choice for Differentiated Thyroid Cancer. International Journal of Surgical Oncology, 2019, 2019, 1-7.	0.3	5
52	Early occurrence of a thyroid carcinoma in a patient who developed Gravesâ€™ disease after treatment for Hodgkinâ€™s disease. Journal of Endocrinological Investigation, 1995, 18, 869-871.	1.8	4
53	The new AJCC/TNM Staging System (VIII ed.) in papillary thyroid cancer: clinical and molecular impact on overall and recurrence free survival. Annals of Translational Medicine, 2020, 8, 838-838.	0.7	4
54	Giant parathyroid adenoma: a rare cause of primary hyperparathyroidism mimicking a carcinoma. Endokrynologia Polska, 2020, 71, 359-360.	0.3	3

#	Article	IF	Citations
55	Response: Re: Papillary Thyroid Cancer Incidence in the Volcanic Area of Sicily. Journal of the National Cancer Institute, 2010, 102, 915-916.	3.0	2
56	Reply to the Letter to the Editor by Sollini M et al.. Journal of Endocrinological Investigation, 2016, 39, 487-488.	1.8	2
57	Response to Letter to the Editor: â€œTime to Separate Persistent From Recurrent Differentiated Thyroid Cancer: Different Conditions With Different Outcomesâ€. Journal of Clinical Endocrinology and Metabolism, 2019, 104, 5110-5111.	1.8	2
58	A novel RET gene mutation in a patient with apparently sporadic pheochromocytoma. Endocrine Journal, 2016, 63, 87-91.	0.7	1
59	Absorbed Dose Evaluation in Radioiodine Therapy with Different Approaches. Instruments, 2019, 3, 39.	0.8	1
60	Metastatic malignant struma ovarii with coexistence of Hashimotoâ€™s thyroiditis. Endocrinology, Diabetes and Metabolism Case Reports, 2016, 2016, 160030.	0.2	1
61	Consenso europeo para el tratamiento de los pacientes con carcinoma tiroideo diferenciado del epitelio folicular. Endocrinologia Y Nutricion: Organo De La Sociedad Espanola De Endocrinologia Y Nutricion, 2007, 54, 390.e1-390.e16.	0.8	0
62	EP-1773 Radioiodine therapy: a dosimetric study in a patient with DTC after rhTSH stimulation. Radiotherapy and Oncology, 2019, 133, S958.	0.3	0
63	Prognostic factors in adrenocortical carcinoma: data from a large Polish series. Polish Archives of Internal Medicine, 2018, 128, 330-332.	0.3	0